Minimally invasive versus open liver resection for nonmetastatic hepatocellular carcinoma staged BCLC - B and - C: an Italian multicentric analysis.

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Hpb Pub Date : 2025-01-23 DOI:10.1016/j.hpb.2025.01.009

Gianluca Cassese, Mariano C Giglio, Alessandro Vitale, Andrea Lauterio, Matteo Serenari, Federica Cipriani, Francesco Ardito, Pasquale Perri, Daniele Nicolini, Giulio Di Gioia, Andrea Pierluigi Fontana, Quirino Lai, Simone Conci, Luca Fumagalli, Maurizio Iaria, Mattia Garancini, Sarah Molfino, Matteo Zanello, Giuliano La Barba, Maria Conticchio, Paola Germani, Simone Famularo, Maurizio Romano, Giuseppe Zimmitti, Michela De Angelis, Albert Troci, Andrea Belli, Francesco Izzo, Michele Crespi, Luigi Boccia, Mohamed Abu Hilal, Giacomo Zanus, Guido Torzilli, Paola Tarchi, Riccardo Memeo, Giorgio Ercolani, Elio Jovine, Gianluca Baiocchi, Fabrizio Romano, Raffaele Della Valle, Marco Chiarelli, Andrea Ruzzenente, Massimo Rossi, Alessandro Ferrero, Marcello Maestri, Marco Vivarelli, Gian Luca Grazi, Felice Giuliante, Luca Aldrighetti, Matteo Cescon, Luciano De Carlis, Umberto Cillo, Roberto I Troisi

{"title":"Minimally invasive versus open liver resection for nonmetastatic hepatocellular carcinoma staged BCLC - B and - C: an Italian multicentric analysis.","authors":"Gianluca Cassese, Mariano C Giglio, Alessandro Vitale, Andrea Lauterio, Matteo Serenari, Federica Cipriani, Francesco Ardito, Pasquale Perri, Daniele Nicolini, Giulio Di Gioia, Andrea Pierluigi Fontana, Quirino Lai, Simone Conci, Luca Fumagalli, Maurizio Iaria, Mattia Garancini, Sarah Molfino, Matteo Zanello, Giuliano La Barba, Maria Conticchio, Paola Germani, Simone Famularo, Maurizio Romano, Giuseppe Zimmitti, Michela De Angelis, Albert Troci, Andrea Belli, Francesco Izzo, Michele Crespi, Luigi Boccia, Mohamed Abu Hilal, Giacomo Zanus, Guido Torzilli, Paola Tarchi, Riccardo Memeo, Giorgio Ercolani, Elio Jovine, Gianluca Baiocchi, Fabrizio Romano, Raffaele Della Valle, Marco Chiarelli, Andrea Ruzzenente, Massimo Rossi, Alessandro Ferrero, Marcello Maestri, Marco Vivarelli, Gian Luca Grazi, Felice Giuliante, Luca Aldrighetti, Matteo Cescon, Luciano De Carlis, Umberto Cillo, Roberto I Troisi","doi":"10.1016/j.hpb.2025.01.009","DOIUrl":null,"url":null,"abstract":"Background: Recent papers report significant survival gain after liver resection in BCLC-B and -C HCC patients. The results of minimally invasive liver surgery (MILS) in such patients have not been widely investigated so far.Methods: Data regarding patients undergoing MILS or open liver resection (OLR) for HCC staged BCLC -B and -C were extracted from the HERCOLES database. An inverse probability of treatment weighting (IPTW) method was adopted to balance the confounders. The primary outcome was a composite endpoint including post-hepatectomy liver failure, severe postoperative complications and in-hospital mortality.Results: 627 patients were included (459 undergoing OLR and 168 receiving MILS). After IPTW, no difference was found in the composite endpoint between MILS and OLR (OR 0.86 [95%CI 0.46-1-60]; p = 0.62). MILS reduced the risk of receiving intra-operative transfusions (OR 0.28 [95%CI 0.13-0.58]; p < 0.001) and of developing postoperative ascites (OR 0.56 [95%CI 0,32-0,98]; p = 0.039), with reduced length of stay (OR 0.82 [95%CI 0.66-1.01]; p = 0.045). The survival analysis showed no differences between MILS and OLR for both OS (p = 0.13) and DFS (p = 0.491).Conclusion: MILS was shown to be safe and feasible for selected non-metastatic HCC patients staged BCLC B and C, reducing the risk of perioperative transfusions and postoperative ascites, and shortening the length of stay.","PeriodicalId":13229,"journal":{"name":"Hpb","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hpb.2025.01.009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recent papers report significant survival gain after liver resection in BCLC-B and -C HCC patients. The results of minimally invasive liver surgery (MILS) in such patients have not been widely investigated so far.

Methods: Data regarding patients undergoing MILS or open liver resection (OLR) for HCC staged BCLC -B and -C were extracted from the HERCOLES database. An inverse probability of treatment weighting (IPTW) method was adopted to balance the confounders. The primary outcome was a composite endpoint including post-hepatectomy liver failure, severe postoperative complications and in-hospital mortality.

Results: 627 patients were included (459 undergoing OLR and 168 receiving MILS). After IPTW, no difference was found in the composite endpoint between MILS and OLR (OR 0.86 [95%CI 0.46-1-60]; p = 0.62). MILS reduced the risk of receiving intra-operative transfusions (OR 0.28 [95%CI 0.13-0.58]; p < 0.001) and of developing postoperative ascites (OR 0.56 [95%CI 0,32-0,98]; p = 0.039), with reduced length of stay (OR 0.82 [95%CI 0.66-1.01]; p = 0.045). The survival analysis showed no differences between MILS and OLR for both OS (p = 0.13) and DFS (p = 0.491).

Conclusion: MILS was shown to be safe and feasible for selected non-metastatic HCC patients staged BCLC B and C, reducing the risk of perioperative transfusions and postoperative ascites, and shortening the length of stay.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Hpb GASTROENTEROLOGY & HEPATOLOGY-SURGERY

CiteScore

5.60

自引率

3.40%

发文量

244

审稿时长

57 days

期刊介绍： HPB is an international forum for clinical, scientific and educational communication. Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice. Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice. HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields. Abstracted and Indexed in: MEDLINE® EMBASE PubMed Science Citation Index Expanded Academic Search (EBSCO) HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).